New Drugs Update: Three Novel Treatments for SARS-CoV-2

Abstract

Coronavirus disease 2019 (COVID-19) cases were first reported in China in December 2019. As of June 4, 2022, more than 530 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported globally, including more than 6.2 million deaths.1 People of all ages are at risk for SARS-CoV-2 infection and severe illness; however, the probability of serious COVID-19 disease is higher in people 60 years of age or older, those living in a nursing facility or long-term care facility, and people with chronic medical conditions. Mortality is highest in patients older than 70 years of age, regardless of the presence of chronic medical conditions.2 In the last two years, in addition to emergence of COVID-19 testing and vaccines, several antiviral treatments and monoclonal antibodies (mAbs) became available and can be used to reduce their chances of being hospitalized or dying from the disease.